Experts discuss how CDC opioid guidelines reduced prescribing but led to misapplication, affecting patient care and access to pain treatment.
Jim Lichauer, PharmD, BCPS, FASHP
Advertisement
Jim Lichaure, PharmD, BCPS, FASHP, is the senior program director for pharmacy performance Improvement, where he leads initiatives that enhance medication safety, optimize utilization, and advance quality outcomes across healthcare systems.
With more than 30 years of experience as a clinical pharmacy specialist and administrator in both private-sector health systems and the Veterans Health Administration, Jim has expertise in medication utilization, regulatory compliance, safety, quality management, and clinical program leadership.
Jim earned his Doctor of Pharmacy degree from the University of Illinois at Chicago and completed a pharmacy practice residency at Methodist Hospital of Indiana. He is a Board-Certified Pharmacotherapy Specialist (BCPS) and a Fellow of the American Society of Health-System Pharmacists (FASHP).
Articles by Jim Lichauer, PharmD, BCPS, FASHP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
2
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
3
ATTR-CM Incidence, Prevalence Rose Sharply in the US
4
Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care
5